Expression of MUM1, BCL-6, and CD138/syn-1 andBCL-6 gene mutations in AIDS-related primary central nervous system lymphomas
| Case . | Diagnosis . | Immunohistochemistry . | BCL-6 (mut) . | EBV . | |||
|---|---|---|---|---|---|---|---|
| MUM1* . | BCL-6* . | Syn-1* . | EBER . | LMP1* . | |||
| 1 | DLCL | − | 25-50 | − | − | + | − |
| 2 | DLCL | 10-25 | 50-75 | − | + | + | − |
| 3 | DLCL | > 75 | 50-75 | − | − | + | − |
| 4 | IBL | − | − | < 10 | − | + | − |
| 5 | IBL | − | − | > 75 | nd | + | 25-50 |
| 6 | IBL | 25-50 | − | − | − | + | 25-50 |
| 7 | IBL | 25-50 | − | < 10 | nd | + | 10-25 |
| 8 | IBL | 25-50 | − | 50-75 | nd | + | 50-75 |
| 9 | IBL | 50-75 | − | > 75 | nd | + | 50-75 |
| 10 | IBL | 50-75 | − | − | − | + | 25-50 |
| 11 | IBL | 50-75 | − | − | − | + | > 75 |
| 12 | IBL | > 75 | − | < 10 | − | + | 10-25 |
| 13 | IBL | > 75 | − | < 10 | nd | + | > 75 |
| 14 | IBL | > 75 | − | < 10 | nd | + | > 75 |
| 15 | IBL | > 75 | − | > 75 | nd | + | > 75 |
| 16 | DLCL/IBL | − | − | − | + | + | < 10 |
| 17 | DLCL/IBL | − | 10-25 | − | + | + | 10-25 |
| 18 | DLCL/IBL | − | < 10 | − | + | + | < 10 |
| 19 | DLCL/IBL | − | > 75 | 50-75 | nd | + | − |
| 20 | DLCL/IBL | 10-25 | 25-50 | 25-50 | nd | + | 25-50 |
| 21 | DLCL/IBL | 10-25 | 50-75 | − | − | + | 25-50 |
| 22 | DLCL/IBL | 50-75 | − | < 10 | nd | + | 10-25 |
| Case . | Diagnosis . | Immunohistochemistry . | BCL-6 (mut) . | EBV . | |||
|---|---|---|---|---|---|---|---|
| MUM1* . | BCL-6* . | Syn-1* . | EBER . | LMP1* . | |||
| 1 | DLCL | − | 25-50 | − | − | + | − |
| 2 | DLCL | 10-25 | 50-75 | − | + | + | − |
| 3 | DLCL | > 75 | 50-75 | − | − | + | − |
| 4 | IBL | − | − | < 10 | − | + | − |
| 5 | IBL | − | − | > 75 | nd | + | 25-50 |
| 6 | IBL | 25-50 | − | − | − | + | 25-50 |
| 7 | IBL | 25-50 | − | < 10 | nd | + | 10-25 |
| 8 | IBL | 25-50 | − | 50-75 | nd | + | 50-75 |
| 9 | IBL | 50-75 | − | > 75 | nd | + | 50-75 |
| 10 | IBL | 50-75 | − | − | − | + | 25-50 |
| 11 | IBL | 50-75 | − | − | − | + | > 75 |
| 12 | IBL | > 75 | − | < 10 | − | + | 10-25 |
| 13 | IBL | > 75 | − | < 10 | nd | + | > 75 |
| 14 | IBL | > 75 | − | < 10 | nd | + | > 75 |
| 15 | IBL | > 75 | − | > 75 | nd | + | > 75 |
| 16 | DLCL/IBL | − | − | − | + | + | < 10 |
| 17 | DLCL/IBL | − | 10-25 | − | + | + | 10-25 |
| 18 | DLCL/IBL | − | < 10 | − | + | + | < 10 |
| 19 | DLCL/IBL | − | > 75 | 50-75 | nd | + | − |
| 20 | DLCL/IBL | 10-25 | 25-50 | 25-50 | nd | + | 25-50 |
| 21 | DLCL/IBL | 10-25 | 50-75 | − | − | + | 25-50 |
| 22 | DLCL/IBL | 50-75 | − | < 10 | nd | + | 10-25 |
Diffuse large cell lymphoma/immunoblastic lymphoma, AIDS-related primary central nervous system lymphoma cases containing a mixture of large noncleaved cells and large cells, immunoblastic plasmacytoid (see “Patients, materials, and methods” and Larocca et al23).
See Table 1 for abbreviations.
Percentages of MUM1, BCL-6, syn-1, and LMP1+ neoplastic cells were assigned to one of the following categories: 0%, less than 10%, 10% to 25%, 25% to 50%, 50% to 75%, and greater than 75%.